Clinical Policy: Leuprolide Acetate (Eligard, Lupaneta Pack, Lupron Depot, Lupron Depot-Ped)
Reference Number: CP.PHAR.173
Effective Date: 10.01.16
Last Review Date: 08.19
Line of Business: HIM, Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Leuprolide acetate (Eligard®, Lupaneta Pack® [with norethindrone acetate tablets], Lupron Depot®, Lupron Depot-Ped®) is a gonadotropin-releasing hormone (GnRH) receptor agonist.

FDA Approved Indication(s)
Leuprolide acetate is indicated for:
- Palliative treatment of advanced prostate cancer:
  - Leuprolide acetate injection
  - Eligard (7.5, 22.5, 30, 45)
  - Lupron Depot (7.5, 22.5, 30, 45)
- Management of endometriosis, including pain relief and reduction of endometriotic lesions:
  - Lupron Depot (3.75, 11.25)
  - Lupaneta Pack (3.75, 11.25)
Limitation(s) of use: Initial treatment course is limited to 6 months and use is not recommended longer than a total of 12 months due to concerns about adverse impact on bone mineral density.
- Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata [fibroids] administered concomitantly with iron therapy:
  - Lupron Depot (3.75, 11.25)
- Treatment of children with central precocious puberty (CPP):
  - Leuprolide acetate
  - Lupron Depot-Ped (7.5, 11.25, 15, 30)

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that leuprolide acetate, Eligard, Lupaneta Pack, Lupron Depot, and Lupron Depot-Ped are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Prostate Cancer (must meet all):
      1. Diagnosis of prostate cancer;
      2. Request is for leuprolide acetate injection or Eligard/Lupron Depot (7.5 mg, 22.5 mg, 30 mg, 45 mg);
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Request meets one of the following (a, b, or c):
   a. Dose does not exceed leuprolide acetate injection (SC): 1 mg per day;
   b. Dose does not exceed Eligard (SC)/Lupron Depot (IM): 7.5 mg per month, 22.5 mg per 3 months, 30 mg per 4 months, 45 mg per 6 months;
   c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

**Approval duration: 12 months**

B. **Endometriosis** (must meet all):
1. Diagnosis of endometriosis;
2. Request is for Lupron Depot/Lupaneta Pack (3.75 mg, 11.25 mg);
3. Prescribed by or in consultation with a gynecologist;
4. Age ≥ 18 years;
5. Endometriosis as a cause of pain is one of the following (a or b):
   a. Surgically confirmed;
   b. Clinically suspected and member has failed a 3-month trial of one of the following agents within the last year or has a documented intolerance or contraindication to the agent (i, ii or iii):
      i. A nonsteroidal anti-inflammatory drug;
      ii. An oral or injectable depot contraceptive;
      iii. A progestin;
6. Dose does not exceed Lupron Depot/Lupaneta Pack (IM): 3.75 mg per month, 11.25 mg per 3 months.

**Approval duration: 6 months**

C. **Uterine Fibroids** (must meet all):
1. Diagnosis of anemia secondary to uterine leiomyomata (fibroids) confirmed by ultrasound;
2. Request is for Lupron Depot (3.75 mg, 11.25 mg);
3. Prescribed by or in consultation with gynecologist;
4. Age ≥ 18 years;
5. Prescribed preoperatively to reduce fibroid size and improve hematologic control;
6. Dose does not exceed Lupron Depot (IM): 3.75 mg per month, 11.25 mg per 3 months.

**Approval duration: 3 months**

D. **Central Precocious Puberty** (must meet all):
1. Diagnosis of CPP confirmed by all of the following (a through c):
   a. Elevated basal luteinizing hormone (LH) level > 0.2 - 0.3 mIU/L (dependent on type of assay used) and/or elevated leuprolide-stimulated LH level > 3.3 - 5 IU/L (dependent on type of assay used);
   b. Difference between bone age and chronological age was > 1 year (bone age-chronological age;
c. Age at onset of secondary sex characteristics is < 8 years if female, or < 9 years if male;
2. Request is for one of the following products (a or b):
   a. Leuprolide acetate;
   b. Lupron Depot Ped: 7.5 mg, 11.25 mg, 15 mg, 30 mg;
3. Prescribed by or in consultation with a pediatric endocrinologist;
4. Member meets one of the following age requirements (a or b):
   a. Female: 2 - 11 years;
   b. Male: 2 - 12 years;
5. Dose does not exceed the following:
   a. Diagnostic use: Leuprolide acetate: 20 mcg/kg or as needed;
   b. Therapeutic use: Leuprolide acetate (SC): Initial: 50 mcg/kg per day; titrate dose upward by 10 mcg/kg per day if down-regulation is not achieved (higher mcg/kg doses may be required in younger children).
   c. Therapeutic use: Lupron Depot-Ped (IM): 15 mg per month (1-month formulation) or 30 mg per 3 months (3-month formulation) (dosing is weight-based).

Approval duration: 12 months

E. Breast and Ovarian Cancer (off-label) (must meet all):
1. Diagnosis of breast or ovarian cancer;
2. Request is for Lupron Depot (3.75 mg, breast or ovarian cancer or 11.25 mg for ovarian cancer);
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Request meets one of the following:
   a. Breast or ovarian cancer: Dose does not exceed 3.75 mg per month;
   b. Ovarian cancer: Dose does not exceed 11.25 mg per 3 months;
   c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

F. Gender Dysphoria (off-label) (must meet all):
1. Diagnosis of gender dysphoria;
2. Prescribed by or in consultation with an endocrinologist and an expert in gender dysphoria and transgender medicine (e.g., mental health professional such as psychologist, psychiatrist);
3. Age and pubertal development - meets (a or b):
   a. Member has reached or passed through Tanner Stage 2* and is < 18 years of age;
   b. Member is ≥ 18 years of age and has failed to achieve physiologic hormone levels with gender-affirming hormonal therapy (e.g., estrogen, testosterone) unless contraindicated or clinically significant adverse effects are experienced;
4. Member demonstrates understanding of expected GnRH analogue treatment outcomes and has given consent for such treatment;

*Age ranges approximating Tanner Stage 2 pubertal development extend from 8 to 13 years of age in girls and 9 to 14 years of age in boys.
5. If member has a psychiatric comorbidity, member is followed by mental health provider;
6. Psychosocial support will be provided during treatment;
7. Request is not for Luponeta Pack;
8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

G. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Prostate Cancer (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Leuprolide acetate injection or Eligard for prostate cancer and has received this medication for at least 30 days;
2. Request is for leuprolide acetate injection or Eligard/Lupron Depot (7.5 mg, 22.5 mg, 30 mg, 45 mg);
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following:
   a. New dose does not exceed leuprolide acetate injection (SC): 1 mg per day;
   b. New dose does not exceed Eligard (SC)/Lupron Depot (IM): 7.5 mg per month, 22.5 mg per 3 months, 30 mg per 4 months, 45 mg per 6 months;
   c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

B. Endometriosis (must meet all):
1. Previously received medication via Centene benefit or member has previously met initial approval criteria;
2. Request is for Lupron Depot/Lupaneta Pack (3.75 mg, 11.25 mg);
3. Member is responding positively to therapy (e.g., improvement in dysmenorrhea, dyspareunia, pelvic pain/induration/tenderness, or size of endometrial lesions);
4. If request is for a dose increase, new dose does not exceed 3.75 mg per month, 11.25 mg per 3 months.

Approval duration: 6 months
Total duration of therapy should not exceed 12 months.

C. Uterine Fibroids (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Request is for Lupron Depot (3.75 mg, 11.25 mg);
CLINICAL POLICY
Leuprolide Acetate

3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.

**Approval duration: 3 months**
*Total duration of therapy should not exceed 6 months.*

**D. Central Precocious Puberty (must meet all):**
1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Request is for leuprolide acetate or Lupron Depot-Ped;
3. Member is responding positively to therapy (e.g., decreased growth velocity, cessation of menses, softening of breast tissue or testes, arrested pubertal progression);
4. Member meets the following age requirement:
   a. Female: ≤ 11 years;
   b. Male: ≤ 12 years;
5. If request is for a dose increase, new dose does not exceed one of the following:
   a. Leuprolide acetate (SC): Initial: 50 mcg/kg per day; titrate dose upward by 10 mcg/kg per day if down-regulation is not achieved (higher mg/kg doses may be required in younger children);
   b. Lupron Depot-Ped (IM): 15 mg per month (1-month formulation) or 30 mg per 3 months (3-month formulation) (dosing is weight-based).

**Approval duration: 12 months**

**E. Breast and Ovarian Cancer (off-label) (must meet all):**
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lupron Depot for breast cancer or ovarian cancer and has received this medication for at least 30 days;
2. Request is for Lupron Depot (3.75 mg, breast or ovarian cancer or 11.25 mg for ovarian cancer);
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following:
   a. Breast or ovarian cancer: New dose does not exceed 3.75 mg per month;
   b. Ovarian cancer: New dose does not exceed 11.25 mg per 3 months;
   c. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration: 12 months**

**F. Gender Dysphoria (off-label) (must meet all):**
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration: 12 months**
G. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy. 
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

   Appendix A: Abbreviation/Acronym Key
   CPP: central precocious puberty
   DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition
   NCCN: National Comprehensive Cancer Network
   FDA: Food and Drug Administration
   GnRH: gonadotropin-releasing hormone
   LH: luteinizing hormone
**Appendix B: Therapeutic Alternatives**

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs: ibuprofen, naproxen, fenoprofen, ketoprofen, mefenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam</td>
<td>Endometriosis Varies – refer to specific prescribing information</td>
<td>Varies – refer to specific prescribing information</td>
</tr>
<tr>
<td>Combined oral estrogen-progesterone contraceptives: ethinyl estradiol + (desogestrel, ethynodiol diacetate, drospirenone, etonogestrel, levonorgestrel, norelgestromin, norethindrone, norgestimate, or norgestrel); estradiol valerate + dienogest; mestranol + norethindrone</td>
<td>Endometriosis 1 tablet PO QD (may vary per specific prescribing information)</td>
<td>1 tablet per day (may vary per specific prescribing information)</td>
</tr>
<tr>
<td>Progestin-only oral contraceptives: norethindrone</td>
<td>Endometriosis 0.35 mg PO QD</td>
<td>0.35 mg PO QD</td>
</tr>
<tr>
<td>Depot injection progestin contraceptives: medroxyprogesterone acetate</td>
<td>Endometriosis IM: 150 mg per 3 months (every 13 weeks) SC: 104 mg per 3 months (every 12 to 14 weeks)</td>
<td>IM: 150 mg/3 months SC: 104 mg/3 months</td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**Appendix C: Contraindications/Boxed Warnings**

- **Contraindication(s):**
  - Known hypersensitivity to GnRH, GnRH agonist analogs or any of the components of the individual products;
  - Pregnancy;
  - Lupron 3.75 mg/11.25 mg and Lupaneta Pack - the above, plus:
    - Undiagnosed abnormal vaginal bleeding;
    - Breast-feeding;
    - If used with norethindrone acetate:
      - Thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions;
      - Markedly impaired liver function or liver disease;
      - Known or suspected carcinoma of the breast.
- **Boxed warning(s): None reported**
## V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate injection</td>
<td>Prostate cancer</td>
<td>Leuprolide acetate injection (SC): 1 mg per day</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 7.5, 22.5, 30, 45)</td>
<td></td>
<td>Lupron Depot (IM) - 7.5 mg per month; 22.5 mg per 3 months; 30 mg per 4 months; 45 mg per 6 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Eligard 7.5, 22.5, 30, 45)</td>
<td></td>
<td>Eligard (SC) - 7.5 mg per month; 22.5 mg per 3 months; 30 mg per 4 months; 45 mg per 6 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75, 11.25)</td>
<td>Endometriosis</td>
<td>Lupron Depot/Lupaneta Pack (IM) - 3.75 mg per month; 11.25 mg per 3 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupaneta Pack 3.75, 11.25)</td>
<td>Uterine fibroids</td>
<td>Lupron Depot (IM) - 3.75 mg/month, 11.25 mg per 3 months</td>
<td>See regimen</td>
</tr>
</tbody>
</table>
| Leuprolide acetate injection (Lupron Depot-Ped 7.5, 11.25, 15 [1 mo]; 11.25, 30 [3 mo]) | CPP | Leuprolide acetate (SC):  
- Diagnostic: 20 mcg/kg or as needed;  
- Treatment: Initial: 50 mcg/kg/day; titrate dose upward by 10 mcg/kg/day if down-regulation is not achieved (higher mg/kg doses may be required in younger children).  
Lupron Depot-Ped (IM): Monthly administration weight-based starting dose: 7.5 mg (≤ 25 kg), 11.25 mg (> 25 to 37.5 kg), 15 mg (> 37.5 kg) (increase as needed to 15 mg/month); 3-month administration: 11.25 mg or 30 mg | See regimen |
| Leuprolide acetate (Lupron Depot 3.75) | Breast cancer | Lupron Depot (IM) 3.75 mg per month                                           | See regimen  |
| Leuprolide acetate (Lupron Depot 3.75, 11.25) | Ovarian cancer | Lupron Depot (IM) 3.75 mg per month, 11.25 mg per 3 months                   | See regimen  |
VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate injection</td>
<td>Kit: 2.8 mL multi-dose vial (1 mg/0.2 mL)</td>
</tr>
<tr>
<td>Leuprolide acetate (Eligard)</td>
<td>Kit: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month)</td>
</tr>
<tr>
<td>Leuprolide acetate and norethindrone tablets</td>
<td>Pack: 3.75 mg leuprolide acetate syringe (1 month) with 5 mg norethindrone</td>
</tr>
<tr>
<td>(Lupaneta Pack)</td>
<td>tablets</td>
</tr>
<tr>
<td></td>
<td>Pack: 11.25 mg leuprolide acetate syringe (3 month) with 5 mg norethindrone</td>
</tr>
<tr>
<td></td>
<td>tablets</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot)</td>
<td>Prefilled syringe: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45</td>
</tr>
<tr>
<td></td>
<td>mg (6 month)</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75)</td>
<td>Prefilled syringe: 3.75 mg (1 month)</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 11.25)</td>
<td>Prefilled syringe: 11.25 mg (3 month)</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot-Ped)</td>
<td>Prefilled syringe: 7.5 mg (1 month), 11.25 mg (1 month), 15 mg (1 month)</td>
</tr>
<tr>
<td></td>
<td>Prefilled syringe: 11.25 mg (3 month), 30 mg (3 month)</td>
</tr>
</tbody>
</table>

VII. References


Gender Dysphoria

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-
date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1950</td>
<td>Injection, leuprolide acetate (for depot suspension), per 3.75 mg</td>
</tr>
<tr>
<td>J9217</td>
<td>Leuprolide acetate (for depot suspension), 7.5 mg</td>
</tr>
<tr>
<td>J9218</td>
<td>Leuprolide acetate, per 1 mg</td>
</tr>
<tr>
<td>J9219</td>
<td>Leuprolide acetate implant, 65 mg</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.16</td>
<td>02.16</td>
</tr>
</tbody>
</table>

Policy split from CP.PHAR.118.GnRH Analogs.
Prostate cancer – locally confined with radiation therapy; age added 18 or older per PI; max dose added; staging restated per PI
Approval period limited to 6 months total with radiation therapy per guidelines
Prostate cancer – advanced/palliative; age added 18 or older per PI; max dose added; removed preferencing other than a trial of injectables before receiving implant; staging of advanced prostate cancer restated as stage T3 through T4 or high risk through nodal/metastatic disease per guidelines; added confirmation that treatment intent is palliative if designated in PI; approval period extended to q 12 months
Breast cancer – advanced/palliative; age added 18 or older per PI; max dose added; defined advanced as stage IV or recurrent metastatic disease per guidelines; removed requirement for ER/PR+ status as guidelines note status not always clear and that GnRH analogs can be effective in either case; add peri-menopausal status per Zoladex guideline; FDA approved and off-label breast cancer criteria is stated the same based on Zoladex PI and guidelines; added confirmation that treatment intent is palliative as designated in Zoladex PI; approval period; extended to q 12 months
Endometriosis - age added 18 or older per PI; max dose added; removed that surgical diagnosis had to be within last year; for clinical diagnosis, restated failure of one three-month trial to analgesics and/or contraceptives per UpToDate; approval period restated per PIs as follows: 6 months total if Zoladex, up to 12 months total for all others per products.
Endometriosis: Changed 3 month trial of analgesics and/or hormonal contraceptives to NSAIDS and/or hormonal contraceptives.
Per the PI, pregnancy is not a contraindication in cases of advanced breast cancer so it is removed as such in sections I.B and II.B above.
Reviews, Revisions, and Approvals

| Age removed.  
| Formulations added.  
| Off-label NCCN recommended uses added (prostate and breast cancer; doses removed; 3-month injectable requirement removed). | 01.17  
| P&T Approval Date | 02.17  
| Age and dosing added to oncology criteria; age added to gynecology criteria.  
| Positive therapeutic response examples added to oncology and endometriosis criteria.  
| Oncology FDA/NCCN (categories 1 and 2A) indications listed separately.  
| Pelvic pain criteria deleted with direction to suspected endometriosis if appropriate. Endometriosis step therapy edited from estrogen/progestin OC to OC or depot contraceptive or progestin.  
| Total approval duration increased from 6 to 12 months.  
| Concomitant iron therapy and specific time period within which surgery must be performed are removed from fibroid criteria. Total approval duration increased from 3 to 6 months.  
| Specialist requirement added for endometriosis, fibroids, CPP.  
| Safety information removed with exception of pregnancy. | 09.17  
| P&T Approval Date | 11.17  
| 4Q 2018 annual review; policies combined for Centene Medicaid and HIM (HIM.PA.SP51); no significant changes; for oncology, summarized NCCN and FDA-approved uses for improved clarity (limited to diagnosis); specialist involvement in care and continuation of care added; references reviewed and updated. | 08.07.18  
| P&T Approval Date | 11.18  
| Addition of gender dysphoria as off-label use. | 07.16.19  
| P&T Approval Date | 08.19  

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable. The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and
limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the non-formulary policy; HIM.PA.103.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.